[Correspondence] CheckMate 8HW and the future of dual immunotherapy – Authors' reply

We appreciate the comments in response to the CheckMate 8HW trial. In CheckMate 8HW, central confirmation of microsatellite instability-high or mismatch repair-deficient status of metastatic colorectal cancer was defined as one central test result of either an immunohistochemistry-based deficient microsatellite mismatch repair test or a PCR-based microsatellite instability test.1 The use of both testing methodologies can maximise sensitivity but we recognise, as Ghanem and Pérez-Wert highlight, that this is not always feasible in clinical practice.